Adaptimmune

13.03.2023 • News

Adaptimmune and TCR2 Agree Merger

Clinical stage biotechs Adaptimmune and TCR2 Therapeutics have agreed to merge, forming what they said would be a “preeminent cell therapy company focused on creating solid tumors” with projected sales of about $27 billion by 2026.

05.03.2015 • News

Adaptimmune Strengthens Management Team with Key Executive Hires

05.06.2014 • News

Adaptimmune in Cancer Collaboration With GlaxoSmithKline

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Evonik Operations GmbH (Hanau)

Biobased Feedstocks as a Roadmap to Defossilization

Free Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.